Partha Ray

Board-certified surgical oncologist and clinician-scientist with over 20 years of experience in academic surgical practice, NIH/NCI-funded translational cancer research, and biotechnology leadership. Discoverer of FOXC1 as a biomarker in basal-like breast cancer; first or corresponding author on 25+ peer-reviewed publications. Named inventor on patents in the U.S., EU, and Canada; eight podium presentations at major international oncology conferences.

Founder of three ventures, including Onconostic Technologies and 3N Diagnostics. Co-developer of RainDanceEQ™, a DNA + RNA multiomics platform for therapy selection in cancer. Currently serves as CoFounder and Chief Medical Officer of Stratifind, Inc., and Founder and Chairmanof Onconostic Technologies, Inc.

Excels in precision oncology, biomarker discovery, and diagnostics, ready to lead AbbVie's Medical Affairs in Precision Medicine.

Co-Founder, Chairman and Chief Medical & Scientific Officer at Stratifind, Inc. (2025-01 – Present)

Precision oncology company focused on molecular profiling and therapy guidance utilizing integrated DNA and RNA analysis.

• Co-developer of RainDanceEQ™, a DNA + RNA multiomics platform for therapy selection across chemotherapy, immunotherapy, and radiation in solid tumors
• Lead clinical and scientific architect of the underlying treatment-response prediction algorithm; oversees clinical strategy, scientific direction, and physician engagement
• Co-founded the company alongside business co-founder Igor Sokolovsky; leads development of additional diagnostic assays and biopharma-facing biomarker programs

Founder, BOD at Onconostic Technologies, Inc. (2011-01 – Present)

Precision oncology diagnostics company; NIH/NCI SBIR Phase I and Phase II awardee.

• Founded to advance the clinical translation of FOXC1 as a diagnostic, prognostic, predictive, and complementary biomarker in basal-like breast cancer and the broader immuno-oncology space
• Led development and commercialization of a CE-marked in vitro diagnostic assay under an ISO13485-compliant manufacturing framework; oversaw multi-institutional clinical validation studies
• Named inventor on issued patents covering biomarker-based diagnostic methods in the U.S., European Union, and Canada; led strategic IP positioning and patent prosecution

Founder, BOD at 3N Diagnostics (2015-01 – Present)

European subsidiary of Onconostic Technologies, established to lead market entry across the EU and ROW.

• Formulated and oversaw successful product launch strategy across the European Union, Middle East, Southeast Asia, the Far East, and Australia / New Zealand
• Engaged and maintained relationships with thought leaders and academic-clinical KOLs across the EU, Middle East, Southeast Asia, Far East, and Australia / NZ

Clinical Practice — Director, Wound Care Service Line at Onsite Healthcare (2018-01 – 2020-12)

• Oversaw and supervised a four-physician practice; supervised implementation of current wound care clinical practice guidelines
• Introduced and implemented waterjet hydrosurgery for wound debridement

Assistant Professor of Surgery at University of Illinois — Carle Cancer Center (2010-01 – 2016-12)

• Active surgical oncology practice across breast, melanoma, gastrointestinal, hepatobiliary, endocrine, and soft-tissue sarcoma, including minimally invasive and complex open procedures (Whipple, hepatectomy, total gastrectomy, retroperitoneal sarcoma resection, oncoplastic breast surgery, modified radical neck dissection)
• NIH/NCI-funded Principal Investigator in translational cancer research; led multi-institutional biomarker validation studies in collaboration with USC, Cedars-Sinai, the University of Chicago, GEICAM (Spain), the European Institute of Oncology (Milan), and Queen's University Belfast
• Mentored residents, fellows, and medical students; recipient of the Carle Research Institute Excellence in Research Award and the Arnold P. Gold Foundation Humanism and Excellence in Teaching Award

Doctor of Medicine in Medicine – Drexel University College of Medicine (2002-01)

General Surgery Residency in Surgery – UMDNJ – Robert Wood Johnson University Hospital (2002-01 – 2008-12)

Immuno-Oncology Research Fellowship in Immuno-Oncology – Cancer Institute of New Jersey (2004-01 – 2005-12)

Surgical Oncology Fellowship in Surgical Oncology – John Wayne Cancer Institute (2008-01 – 2010-12)